Open AccessBrief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
Author(s) -
DongWan Kim,
Shirish M. Gadgeel,
Scott Gettinger,
Gregory J. Riely,
Geoffrey R. Oxnard,
Tarek Mekhail,
Peter Schmid,
Afshin Dowlati,
Rebecca S. Heist,
Antoinette J. Wozniak,
Jatinder Singh,
Edward Cha,
Jessica Spahn,
SaiHong Ignatius Ou
Publication year - 2022
Publication title -
jto clinical and research reports
Language(s) - English
Resource type - Journals
ISSN - 2666-3643
DOI - 10.1016/j.jtocrr.2022.100367
Subject(s) - alectinib , atezolizumab , medicine , tolerability , adverse effect , oncology , crizotinib , cancer , lung cancer , immunotherapy , nivolumab , malignant pleural effusion
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom